Treatment of adrenal metastases with conventional or hypofractionated image-guided radiation therapy: patterns and outcomes

Background/Aim: Metastases involving the adrenal glands can be treated surgically or with radiation therapy. Retrospective studies indicate that radiotherapy for this indication is safe, well-tolerated and associated with symptom palliation and good local control. We conducted this analysis to repor...

Full description

Saved in:
Bibliographic Details
Main Authors: Bürgy, Daniel (Author) , Rabe, Leonie (Author) , Siebenlist, Kerstin (Author) , Stieler, Florian (Author) , Fleckenstein, Jens (Author) , Giordano, Frank Anton (Author) , Wenz, Frederik (Author) , Boda-Heggemann, Judit (Author)
Format: Article (Journal)
Language:English
Published: 2018
In: Anticancer research
Year: 2018, Volume: 38, Issue: 8, Pages: 4789-4796
ISSN:1791-7530
DOI:10.21873/anticanres.12788
Online Access:Verlag, Volltext: https://doi.org/10.21873/anticanres.12788
Verlag: http://ar.iiarjournals.org/content/38/8/4789
Get full text
Author Notes:Daniel Buergy, Leonie Rabe, Kerstin Siebenlist, Florian Stieler, Jens Fleckenstein, Frank A. Giordano, Frederik Wenz and Judit Boda-Heggemann
Description
Summary:Background/Aim: Metastases involving the adrenal glands can be treated surgically or with radiation therapy. Retrospective studies indicate that radiotherapy for this indication is safe, well-tolerated and associated with symptom palliation and good local control. We conducted this analysis to report on patterns and outcomes of patients with adrenal metastases treated with hypo- or conventionally fractionated image-guided radiotherapy. Patients and Methods: Patients with adrenal metastases from solid tumors treated at our department between 01/2010-12/2017 were reviewed. A total of 22 lesions were treated in 18 patients with a median dose of 35 Gy (20-60 Gy) in a median number of 7 (4-25) fractions. Results: No grade ≥3 toxicity occurred. Median overall survival was 11.9 months. Five local failures occurred (22.7%). Lesion sizes or radiation dose were not correlated with local control. Patients treated for oligometastatic and oligoprogressive disease had a median overall survival of 33 and 6.5 months, respectively (palliative/polymetastatic: 1.6 months). Symptoms improved in all patients treated for clinically apparent lesions. Conclusion: Stereotactic radiotherapy of adrenal metastases was safe and effective in patients with oligometastases or oligoprogression. In palliative patients, short-course radiotherapy complemented with supportive care should be preferred.
Item Description:Gesehen am 24.10.2019
Physical Description:Online Resource
ISSN:1791-7530
DOI:10.21873/anticanres.12788